SystImmune, Inc. Reveals New Findings on Iza-bren for Breast Cancer at ESMO 2025 Conference

SystImmune's Groundbreaking Presentation on Iza-bren

SystImmune, Inc., a clinical-stage biotechnology company, is making headlines with its innovative approach to treating breast cancer. At the upcoming European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress, running from May 14 to 17 in Munich, Germany, they will present exciting new data about their bispecific antibody-drug conjugate (ADC), called izalontamab brengitecan, or Iza-bren. This novel therapy targets both EGFR and HER3, proteins often implicated in the proliferation of various cancers.

Advancements in Clinical Research

The information to be unveiled at the conference stems from ongoing Phase 1 clinical trials specifically focusing on patients with locally advanced or metastatic HER2-negative breast cancer. This presentation is eagerly anticipated by the medical community, particularly in light of SystImmune's recent positive findings. In analysis shared at the SABCS 2024 conference, Iza-bren showed promising efficacy across all HER2 expression levels, including patients classified as HER2 0, which have typically faced limited treatment options.

Jonathan Cheng, M.D., Chief Medical Officer at SystImmune, expressed optimism regarding the results. He stated, "These data continue to support our conviction that Iza-bren demonstrates strong clinical efficacy across a wide variety of tumors such as breast cancer, including HER2 negative breast cancer, with a manageable safety profile. This positions Iza-bren as an important therapeutic option that may address unmet medical needs."

Phase 1 Trial Results

In this Phase 1 study, identified as BL-B01D1, researchers administered Iza-bren to patients whose breast cancer had progressed after previous therapies, aiming to measure its efficacy and safety. Given the results showcased so far, SystImmune is confident that it can effectively contribute to improving treatment outcomes for patients who have exhausted other options.

Additionally, Iza-bren operates by blocking signals from EGFR and HER3 to cancer cells. Upon internalization by these cells, Iza-bren releases a therapeutic payload designed to induce cell death. With its dual-action approach, Iza-bren is not only targeted but also potentially more effective than traditional therapies that address only one receptor signal.

Commitment to Innovation

SystImmune's commitment to advancing cancer treatments extends beyond Iza-bren. The company is actively developing a diverse pipeline of bi-specific and multi-specific antibodies and ADCs, continuously exploring groundbreaking avenues to combat both solid tumors and hematologic malignancies. The collaboration with Bristol Myers Squibb under an exclusivity agreement underscores the importance of these innovations in the battle against cancer.

Looking Ahead

As the presentation date approaches, there is a renewed sense of hope in the oncology field. SystImmune is keen to ascertain how communities of patients and healthcare providers respond to their findings on Iza-bren. Cheng elaborated, "We are committed to advancing this therapy through clinical trials, exploring its potential not only as a monotherapy but also in combination with other agents to improve outcomes for cancer patients globally."

With a robust preclinical pipeline and ongoing clinical trials, SystImmune stands at the forefront of biopharmaceutical innovation with the prospect of transforming how breast cancer is treated. This anticipated presentation at ESMO Breast 2025 is a critical milestone for the company and highlights its dedication to delivering hope to patients battling this devastating disease.

Conclusion

For more information about SystImmune and its initiatives in cancer research, visit SystImmune's official website. The updates on Iza-bren signal a significant advancement in therapeutic options available for advanced breast cancer, offering hope to patients who may have otherwise exhausted standard treatment paths.